ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1200

Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years

Karen Costenbader1, Nancy R Cook2, I-Min Lee2, Jill Hahn3, Joseph Walter1, Vadim Bubes1, Gregory Kotler1, Nicole Yang1, Sonia Friedman1, Erik K Alexander1 and JoAnn E Manson2, 1Brigham and Women's Hospital, Boston, MA, 2Harvard TH Chan School of Public Health, Brigham and Women's Hospital, Boston, MA, 3Brigham and Womens' Hospital, Boston, MA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, clinical trial, diet, prevention

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Strong biologic rationale supports potential effects of both vitamin D and of marine omega-3 (n3) fatty acids for autoimmune disease prevention. Within the randomized double-blind, placebo-controlled VITamin D and OmegA-3 TriaL (VITAL), we tested the effects of these supplements on autoimmune disease incidence. We previously reported results after 5.3 years of randomized follow-up showing overall protective effects for vitamin D on incidence of all autoimmune diseases (hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.61-0.99) and suggestive effect for n-3 fatty acids (HR 0.85, 95%CI 0.67-1.08) (Hahn J et al, BMJ, 2022). We now test the effects of these 2 supplements with 2 more years of post-intervention follow-up in VITAL to determine if the effects were sustained after the intervention ended.

Methods: VITAL enrolled and randomized men and women (age >50 and >55 years, respectively) in a two-by-two factorial design to receive vitamin D3 (2000 IU/d) and/or n3 fatty acids (1000 mg/d) or placebo and followed them for median of 5.3 years. Here, we followed surviving and willing participants (85%) for another 2 years of observation to assess for sustained effects. Incident diagnoses of autoimmune diseases were reported by participants annually and confirmed by medical record review by expert physicians using classification criteria. The primary endpoint was all confirmed incident autoimmune diseases, including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), autoimmune thyroid disease, psoriasis, and others. Pre-specified secondary endpoints included confirmed and probable cases, and individual autoimmune diseases. HRs for incident autoimmune diseases were calculated using Cox regression models.

Results: 25,871 participants were randomized: 71% self-reported as non-Hispanic Whites, 20% Black, and 9% other racial/ethnic groups; 51% women; mean age 67.1 years. During median follow-up of 7.3 years, confirmed autoimmune disease was diagnosed in 234 participants in the vitamin D3 group and 240 in the placebo group, HR 0.97 (0.81-1.17). (Table 1A) Confirmed autoimmune disease was diagnosed in 221 participants in the n3 fatty acids group and 253 in the placebo group, HR 0.87 (0.73-1.04). For vitamin D, HRs were RA 0.83 (0.51-1.35), PMR 0.89 (0.62-1.27) and psoriasis 0.61 (0.38-0.96). For n3 fatty acids, HRs trended toward reduction for RA 0.64 (0.39-1.06) and autoimmune thyroid disease 0.64 (0.38-1.08), but psoriasis was increased 1.72 (1.09-2.80). In the 2×2 factorial groups, all intervention arms continued to have more reduced incidence of new autoimmune diseases than did the placebo/placebo arm. (Figure) The effect of vitamin D on autoimmune disease incidence was stronger among those with body mass index (BMI) < 25 kg/m2 compared to ≥ 25 kg/m2 (p-interaction 0.01).

Conclusion: 2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in this trial over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. By contrast, 1000 mg/day of n3 fatty acids led to borderline reduction of autoimmune disease incidence over 5.3 years, with minimal change after 2 years of post-trial follow-up.

Supporting image 1

Supporting image 2


Disclosures: K. Costenbader, Eli Lilly, Janssen, Amgen, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline(GSK), Gilead, Exagen, Neutrolis, Cel-Sci, Alkermes; N. Cook, None; I. Lee, None; J. Hahn, None; J. Walter, None; V. Bubes, None; G. Kotler, None; N. Yang, None; S. Friedman, None; E. Alexander, None; J. Manson, None.

To cite this abstract in AMA style:

Costenbader K, Cook N, Lee I, Hahn J, Walter J, Bubes V, Kotler G, Yang N, Friedman S, Alexander E, Manson J. Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/vitamin-d-and-marine-n-3-fatty-acid-supplementation-for-prevention-of-autoimmune-disease-in-the-vital-randomized-controlled-trial-outcomes-over-7-years/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vitamin-d-and-marine-n-3-fatty-acid-supplementation-for-prevention-of-autoimmune-disease-in-the-vital-randomized-controlled-trial-outcomes-over-7-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology